Cited by 137Hepatitis Viruses Studies and EpidemiologyHepatitis B Virus StudiesViral gastroenteritis research and epidemiology

The DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.

Immunoglobulin prophylaxis for hepatitis A.

Winokur, P. L., Stapleton, J. T.·1992·Clinical Infectious Diseases

DOI 10.1093/clinids/14.2.580

Open this paper in CoChat — free account

Abstract

Studies conducted over the past 45 years have shown that immunoglobulin (IG) prevents 80%-90% of cases of hepatitis A when administered before exposure or shortly thereafter. Protection is short lived and requires early diagnosis and timely administration of IG to contacts. Inactivated and attenuated hepatitis A virus (HAV) vaccines have recently been developed and should be available for clinical use within the next few years. Evaluation of antibodies to HAV in IG and in IG recipients provides one method of determining the immunogenicity of HAV vaccines. The role of IG in the prevention of hepatitis A is reviewed with emphasis on the relationship of antibody response following IG administration to the efficacy of HAV vaccines.

Integrity signals

Registry

Crossref · 10.1093/clinids/14.2.580

Cites

73 of 73 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Hepatitis A: Detection by Immune Electron Microscopy of a Viruslike Antigen Associated with Acute Illness
Feinstone, S. M., Kapikian, A. Z., & Purcell, R. H. (1973) · Science · doi:10.1126/science.182.4116.1026 · Cited by 865
CHEMICAL, CLINICAL, AND IMMUNOLOGICAL STUDIES ON THE PRODUCTS OF HUMAN PLASMA FRACTIONATION. I. THE CHARACTERIZATION OF THE PROTEIN FRACTIONS OF HUMAN PLASMA 12
Cohn, E. J., Oncley, J. L., Strong, L. E., Hughes, W. L., & Armstrong, S. H. (1944) · Journal of Clinical Investigation · doi:10.1172/jci101508 · Cited by 407
Hepatitis A Virus
Zachoval, V. G.-M. A. R. (2003) · CRC Press eBooks · doi:10.1201/b14823-11 · Cited by 362
FREQUENCY OF ILLNESS ASSOCIATED WITH EPIDEMIC HEPATITIS A VIRUS INFECTIONS IN ADULTS
Lednar, W. M., Lemon, S. M., Kirkpatrick, J. W., Redfield, R. R., Fields, M. L., & Kelley, P. W. (1985) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a114093 · Cited by 341
Type A Viral Hepatitis
Lemon, S. M. (1985) · New England Journal of Medicine · doi:10.1056/nejm198510243131706 · Cited by 338
Hepatitis A in Day-Care Centers
Hadler, S. C., Webster, H., Erben, J. J., Swanson, J. E., & Maynard, J. E. (1980) · New England Journal of Medicine · doi:10.1056/nejm198005293022203 · Cited by 300
ANAPHYLACTOID TRANSFUSION REACTIONS ASSOCIATED WITH ANTI-IgA
Vyas, G. N., Perkins, H. A., & Fudenberg, H. H. (1968) · The Lancet · doi:10.1016/s0140-6736(68)90527-8 · Cited by 291
THE PREVENTION AND ATTENUATION OF INFECTIOUS HEPATITIS BY GAMMA GLOBULIN
Stokes, J. (1945) · JAMA · doi:10.1001/jama.1945.02860030016004 · Cited by 290
Molecular epidemiology of human hepatitis A virus defined by an antigen-capture polymerase chain reaction method.
Jansen, R. W., Siegl, G., & Lemon, S. M. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.8.2867 · Cited by 270
Biological and immunological properties of human immunodeficiency virus type 1 envelope glycoprotein: analysis of proteins with truncations and deletions expressed by recombinant vaccinia viruses
Earl, P. L., Koenig, S., & Moss, B. A. (1991) · Journal of Virology · doi:10.1128/jvi.65.1.31-41.1991 · Cited by 230

Show all 73 references

Sorted by citations

Sexually Transmitted Infections Treatment Guidelines, 2021
Workowski, K. A., Bachmann, L. H., Chan, P. A., Johnston, C. M., Muzny, C. A., Park, I., Reno, H., Zenilman, J. M., & Bolan, G. A. (2021) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr7004a1 · Cited by 3,018
Sexually Transmitted Diseases Treatment Guidelines, 2010
Workowski, K., & BOLAN, G. A. (2011) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2011.04.006 · Cited by 2,074
Recommendations of the Advisory Committee on Immunization Practices (ACIP)
Harpaz, R., Ortega‐Sanchez, I. R., & Seward, J. F. (2008) · Cited by 1,302
Prevention of Hepatitis A Through Active or Passive Immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
Fiore, A. E., Wasley, A., & Bell, B. P. (1999) · PsycEXTRA Dataset · doi:10.1037/e547812006-001 · Cited by 1,130
Immunisation against infectious disease
SALISBURY, D. M., Ramsay, M. E., & Noakes, K. (2006) · Stationery Office eBooks · Cited by 636
Hepatitis A: Old and New
Cuthbert, J. A. (2001) · Clinical Microbiology Reviews · doi:10.1128/cmr.14.1.38-58.2001 · Cited by 474
Hepatitis A Transmitted by Food
Fiore, A. E. (2004) · Clinical Infectious Diseases · doi:10.1086/381671 · Cited by 351
“period [60].”
Hepatitis A in the Era of Vaccination
Wasley, A. (2006) · Epidemiologic Reviews · doi:10.1093/epirev/mxj012 · Cited by 295
“06 ml/kg protects for up to 5 months (37).”
Background
Hepatitis A
Koff, R. S. (1998) · The Lancet · doi:10.1016/s0140-6736(98)01304-x · Cited by 265
Prevention of Hepatitis A Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2020
Nelson, N. P., Weng, M. K., Hofmeister, M. G., Moore, K. L., Doshani, M., Kamili, S., Koneru, A., Haber, P., Hagan, L., Romero, J. R., et al. (2020) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr6905a1 · Cited by 264
International Handbook of Foodborne Pathogens
Miliotis, M. D. (2003) · CRC Press eBooks · doi:10.1201/9780203912065 · Cited by 248
Clinical experience with an inactivated hepatitis A vaccine.
Clemens, R., Safary, A., Hepburn, A., Roche, C., Stanbury, W. J., & Andre, F. E. (1995) · Journal of Infectious Diseases · doi:10.1093/infdis/171.supplement_1.s44 · Cited by 223
“Although immune serum globulin (ISG) offers effective passive protection (~-85%) against hepatitis A for travelers [9], patient compliance is low because of a number of factors including lack of information on availability, its cost, injection site pain, and the fact that immunoglobulins are bloodderived products.”
Background
Efficacy of hepatitis A vaccine in prevention of secondary hepatitis A infection: a randomised trial
Sagliocca, L., Amoroso, P., Stroffolini, T., Adamo, B., Tosti, M. E., Lettieri, G., Esposito, C., Buonocore, S., Pierri, P., & Mele, A. (1999) · The Lancet · doi:10.1016/s0140-6736(98)08139-2 · Cited by 173
A Program to Control an Outbreak of Hepatitis A in Alaska by Using an Inactivated Hepatitis A Vaccine
McMahon, B. J. (1996) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/archpedi.1996.02170320079014 · Cited by 163
Host Immune Response To Hepatitis A Virus
Stapleton, J. T. (1995) · The Journal of Infectious Diseases · doi:10.1093/infdis/171.supplement_1.s9 · Cited by 129
“Several additional studies confirm the efficacy of preexposure prophylaxis for HAV infection with ISG (reviewed in [19]).”
BackgroundInfluential
SAFETY AND EFFICACY OF HEPATITIS A VACCINATION IN LIVER TRANSPLANTATION RECIPIENTS1, 2
Arslan, M., Wiesner, R. H., Poterucha, J. J., & Zein, N. N. (2001) · Transplantation · doi:10.1097/00007890-200107270-00019 · Cited by 111
Neutralizing Antibodies Protect against Lethal Flavivirus Challenge but Allow for the Development of Active Humoral Immunity to a Nonstructural Virus Protein
Kreil, T. R., Maier, E., Fraiss, S., & Eibl, M. M. (1998) · Journal of Virology · doi:10.1128/jvi.72.4.3076-3081.1998 · Cited by 76
Travel Vaccines and Elderly Persons: Review of Vaccines Available in the United States
Leder, K. S., Weller, P. F., & Wilson, M. E. (2001) · Clinical Infectious Diseases · doi:10.1086/322968 · Cited by 67
“Cell-mediated reactions may play a minor role in the immune response to hepatitis A infection, but antibody alone is sufficient to protect against clinical disease, as has been clearly demonstrated by the excellent protection provided by passive immunization with Ig [11, 12].”
Background
Hepatitis A antibody titres after infection and immunization: implications for passive and active immunization
Zaaijer, H. L., Leentvaar-Kuijpers, A., Rotman, H. A. J., & Lelie, P. N. (1993) · Journal of Medical Virology · doi:10.1002/jmv.1890400106 · Cited by 61
Four treatment failures of pharyngeal gonorrhoea with ceftriaxone (500 mg) or cefotaxime (500 mg), Sweden, 2013 and 2014
Golparian, D., Ohlsson, A. K., Janson, H., Lidbrink, P., Richtner, T., Ekelund, O., Fredlund, H., & Unemo, M. (2014) · Eurosurveillance · doi:10.2807/1560-7917.es2014.19.30.20862 · Cited by 60
Sexually acquired hepatitis
Brook, M. G. (2002) · Sexually Transmitted Infections · doi:10.1136/sti.78.4.235 · Cited by 57
Cost‐effectiveness analysis of vaccination against hepatitis A in travellers
van Doorslaer, E. K. A., Tormans, G., & Damme, P. V. (1994) · Journal of Medical Virology · doi:10.1002/jmv.1890440429 · Cited by 57
Hepatitis A virus-specific humoral and cellular immune responses following immunization with a formalin-inactivated hepatitis A vaccine
Cederna, J. B., Klinzman, D., & Stapleton, J. T. (1999) · Vaccine · doi:10.1016/s0264-410x(99)00342-4 · Cited by 55
Effect of postexposure vaccination in a chimpanzee model of hepatitis A virus infection
Robertson, B. H., D'Hondt, E., Spelbring, J. E., Tian, H., Krawczyński, K., & Margolis, H. S. (1994) · Journal of Medical Virology · doi:10.1002/jmv.1890430310 · Cited by 55
Immunoprecipitation and Virus Neutralization Assays Demonstrate Qualitative Differences between Protective Antibody Responses to Inactivated Hepatitis A Vaccine and Passive Immunization with Immune Globulin
Lemon, S. M., Murphy, P. C., PROVOST, P. J., Chalikonda, I., Davide, J. P., Schofield, T. L., Nalin, D. R., & Lewis, J. A. (1997) · The Journal of Infectious Diseases · doi:10.1086/514044 · Cited by 53
Immunologic approaches to assessing the response to inactivated hepatitis A vaccine
Lemon, S. M. (1993) · Journal of Hepatology · doi:10.1016/s0168-8278(05)80372-1 · Cited by 52
Cost-benefit analysis of a nationwide infant immunization programme against hepatitis A in an area of intermediate endemicity
Ginsberg, G. M., Slater, P. E., & Shouval, D. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(00)00007-6 · Cited by 51
An extra priming dose of hepatitis A vaccine to adult patients with rheumatoid arthritis and drug induced immunosuppression – A prospective, open-label, multi-center study
Rosdahl, A., Herzog, C., Frösner, G., Norén, T., Rombo, L., & Askling, H. H. (2017) · Travel Medicine and Infectious Disease · doi:10.1016/j.tmaid.2017.12.004 · Cited by 47
Clinical development of a new inactivated hepatitis a vaccine
Vidor, E. J., Fritzell, B., & Plotkin, S. A. (1996) · Infection · doi:10.1007/bf01713047 · Cited by 48
Viral Hepatitis
Margolis, H. S., Alter, M. J., & Hadler, S. C. (1997) · Springer eBooks · doi:10.1007/978-1-4899-0036-4_13 · Cited by 47
Assay of humoral immunity to mumps virus
Pipkin, P. A., Afzal, M., Heath, A., & Minor, P. D. (1999) · Journal of Virological Methods · doi:10.1016/s0166-0934(99)00019-1 · Cited by 46
A Phase 2b Study to Evaluate the Safety and Efficacy of VRC01 Broadly Neutralizing Monoclonal Antibody in Reducing Acquisition of HIV-1 Infection in Women in Sub-Saharan Africa: Baseline Findings
Mgodi, N. M., Takuva, S. G., Edupuganti, S., Karuna, S., Andrew, P., Lazarus, E. M., Garnett, P., Shava, E., Mukwekwerere, P. G., Kochar, N. K., et al. (2021) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000002649 · Cited by 44
Antigenic and immunogenic properties of recombinant hepatitis A virus 14S and 70S subviral particles
Stapleton, J. T., Raina, V., Winokur, P. L., Walters, K., Klinzman, D., Rosen, E. D., & McLinden, J. H. (1993) · Journal of Virology · doi:10.1128/jvi.67.2.1080-1085.1993 · Cited by 44
Testing for Antibody to Hepatitis A to Decrease the Cost of Hepatitis A Prophylaxis With Immune Globulin or Hepatitis A Vaccines
Bryan, J. P. (1994) · Archives of Internal Medicine · doi:10.1001/archinte.154.6.663 · Cited by 44
Passive immunization against hepatitis A
Stapleton, J. T. (1992) · Vaccine · doi:10.1016/0264-410x(92)90541-q · Cited by 43
Antibody-Based Strategies to Prevent and Treat Influenza
Shriver, Z. H., Trevejo, J., & Sasisekharan, R. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00315 · Cited by 40
“Additionally, post-exposure prophylaxis with immunoglobulin is >85% effective in preventing hepatitis A if administered within 2weeks after viral exposure, and efficacy is evenhigherwhen administered early in the incubation period (14).”
Background
Hepatitis A antibodies in liver transplant recipients: Evidence for loss of immunity posttransplantation
Arslan, M., Wiesner, R. H., Poterucha, J. J., Gross, J. B., & Zein, N. N. (2000) · Liver Transplantation · doi:10.1002/lt.500060216 · Cited by 39
Epidemiology and Prevention of Hepatitis A in Travelers
Dong, W., & Guo, C. (2013) · Journal of Travel Medicine · doi:10.1111/jtm.12058 · Cited by 38
Foodborne outbreak of hepatitis A, November 2007–January 2008, Austria
Schmid, D., Fretz, R., Buchner, G., König, C., Perner, H., Sollak, R., Tratter, A., Hell, M., Maaß, M., Straßer, M., et al. (2008) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-008-0633-0 · Cited by 36
“Postexposure prophylaxis with immunoglobulin is >85% effective in preventing hepatitis A if administered within 2 weeks after exposure to HAV [29].”
Background
Aventis Pasteur Vaccines Containing Inactivated Hepatitis A Virus: A Compilation of Immunogenicity Data
Porteret, V., Bailleux, F., Veitch, K., Dumas, R., & Vidor, E. J. (2004) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-003-1094-0 · Cited by 33
“Historical passive protection experiments [65] have shown clinical protection to be extremely good in subjects with very low or even undetectable levels of specific HAV antibodies when measured by conventional antibody assays.”
Background
The Endemic Infectious Diseases of Somalia
Oldfield, E. C., Rodier, G. R., & Gray, G. C. (1993) · Clinical Infectious Diseases · doi:10.1093/clinids/16.supplement_3.s132 · Cited by 33
“Studies have shown that ISG can prevent 80%-90% of cases if given before or up to 2 weeks after exposure [ 101].”
Background
Immunogenicity of an inactivated hepatitis A vaccine administered according to two different schedules and the interference of other “travellers” vaccines with the immune response
Bienzle, U., Bock, H. L., Kruppenbacher, J. P., Hofmann, F. M., Vogel, G., & Clemens, R. L. (1996) · Vaccine · doi:10.1016/0264-410x(95)00224-o · Cited by 31
Hepatitis A vaccine. A new convenient single-dose schedule with booster when long-term immunization is warranted
Victor, J., Knudsen, J. D., Nielsen, L. P., Fomsgaard, A., Thybo, S., Bygbjerg, I. C., & Westh, H. (1994) · Vaccine · doi:10.1016/s0264-410x(94)80028-x · Cited by 31
Hepatitis A Virus
Spradling, P. R., Martin, A., & Feinstone, S. M. (2009) · doi:10.1128/9781555815981.ch47 · Cited by 31
Hepatitis A And The American Traveler
Wolfe, M. S. (1995) · The Journal of Infectious Diseases · doi:10.1093/infdis/171.supplement_1.s29 · Cited by 30
“ISG remains a highly effective method of preventing hepatitis A (table 2) [15-20], and it is considered safe for both adults and children and for pregnant women and immunosuppressed persons [20].”
BackgroundMethod
Cost Effectiveness of Hepatitis A Virus Immunisation in Spain
Arnal, J., Frisas, O., Garuz, R., & Antoñanzas, F. (1997) · PharmacoEconomics · doi:10.2165/00019053-199712030-00008 · Cited by 30
Neutralizing human monoclonal antibodies to hepatitis A virus recovered by phage display
Kim, S. J., Jang, M. H., Stapleton, J. T., Yoon, S. O., Kim, K., Jeon, E., & Hong, H. J. (2003) · Virology · doi:10.1016/j.virol.2003.10.014 · Cited by 29
Hepatitis A: post-exposure prophylaxis
Taliani, G., & Gaeta, G. B. (2003) · Vaccine · doi:10.1016/s0264-410x(03)00138-5 · Cited by 29
Safety and effectiveness of the new inactivated hepatitis A virus vaccine.
Furesz, J., Scheifele, D. W., & Palkonyay, L. (1995) · Europe PMC (PubMed Central) · Cited by 28
Sexual transmission and prevention of the hepatitis viruses A-E and G
Brook, M. G. (1998) · Sexually Transmitted Infections · doi:10.1136/sti.74.6.395 · Cited by 24
Good immunogenicity of GBM strain inactivated hepatitis A vaccine in healthy male adults
Garín, D., Vidor, E. J., Wallon, M., Fanget, B., Brasseur, P., Delolme, H., Caron, F., Mojon, M., Gravey, A., Humbert, G., et al. (1995) · Vaccine · doi:10.1016/0264-410x(95)93140-5 · Cited by 24
Safety and immunogenicity of an inactivated hepatitis A vaccine in children 2 to 5 years old
Arı́stegui, J., Garrote, E., Morales, J. L., Gallego, M. S., Dal−Ré, R., & González, A. (1995) · Infection · doi:10.1007/bf01716302 · Cited by 21
Management of Hepatitis A in 2020-2021
Desai, A. N., & Kim, A. Y. (2020) · JAMA · doi:10.1001/jama.2020.4017 · Cited by 20
Synthesis of immunogenic hepatitis A virus particles by recombinant baculoviruses
Rosen, E. D., Stapleton, J. T., & McLinden, J. H. (1993) · Vaccine · doi:10.1016/0264-410x(93)90253-t · Cited by 20
An Outbreak of Hepatitis A in an Intensive Care Unit
Hanna, J. N., Loewenthal, M. R., Negel, P., & Wenck, D. J. (1996) · Anaesthesia and Intensive Care · doi:10.1177/0310057x9602400405 · Cited by 20
Back to the future: Antibody-based strategies for the treatment of infectious diseases
Oral, H. B., Özakın, C., & Akdiş, C. A. (2002) · Molecular Biotechnology · doi:10.1385/mb:21:3:225 · Cited by 19
Hepatitis A vaccines
Fiore, A. E., Feinstone, S. M., & Bell, B. P. (2008) · Elsevier eBooks · doi:10.1016/b978-1-4160-3611-1.50016-7 · Cited by 19
Evaluation of inactivated hepatitis A vaccine in Canadians 40 years of age or more.
Scheifele, D. W., & Bjornson, G. J. (1993) · Europe PMC (PubMed Central) · Cited by 19
Response to Hepatitis A Vaccine in Children after a Single Dose with a Booster Administration 6 Months Later
Findor, J., Velasco, M., Mutti, J., & Safary, A. (1996) · Journal of Travel Medicine · doi:10.1111/j.1708-8305.1996.tb00730.x · Cited by 18
A simple and rapid Hepatitis A Virus (HAV) titration assay based on antibiotic resistance of infected cells: evaluation of the HAV neutralization potency of human immune globulin preparations
Konduru, K., Virata, M. L., Yu, M.-Y. W., & Kaplan, G. G. (2008) · Virology Journal · doi:10.1186/1743-422x-5-155 · Cited by 17
“Human IG preparations are recommended for HAV preand post-exposure prophylaxis [11,12].”
Background
Severe hepatitis A despite passive immunisation
Behrens, R. H., & Doherty, J. (1993) · The Lancet · doi:10.1016/0140-6736(93)91274-p · Cited by 16
Impact of Electronic Laboratory Reporting on Hepatitis A Surveillance in New York City
Moore, K. M., Reddy, V., Kapell, D., & Balter, S. (2008) · Journal of Public Health Management and Practice · doi:10.1097/01.phh.0000333877.78443.f0 · Cited by 15
Long-term protective effect of post-exposure Havrix TM administration during viral hepatitis Type A outbreaks
Kohl, I., Němeček, V., Summerová, M., Chlíbek, R., Naďová, K., & Mináriková, O. (2006) · European Journal of Epidemiology · doi:10.1007/s10654-006-9081-2 · Cited by 15
“This may also represent a bias in favour of the HNIG group, since protection is immediate following intramuscular injection of HNIG, and is most effective when administered early in the incubation period [1, 19], while in contrast, up to two weeks are necessary for protection following hepatitis A vaccination [20, 21].”
Background
Functional recombinant human anti-HAV antibody expressed in milk of transgenic mice
Zhang, R., Rao, M., Li, C., Cao, J., Meng, Q., Zheng, M., Wang, M., Dai, Y., Liang, M., & Li, N. (2009) · Transgenic Research · doi:10.1007/s11248-008-9241-0 · Cited by 15
“Besides, in different culture conditions, there are pitfalls in complicated purification steps as well as variable mAbs levels and posttranslational modifications (Castillo 1999; Farid 2007; Kozlowski and Swann 2006; Winokur and Stapleton 1992).”
Background
Global dissemination of β2-lactamases mediating resistance to cephalosporins and carbapenems
Gootz, T. D. (2004) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2.2.317 · Cited by 15
POSTEXPOSURE PROPHYLAXIS
Lutwick, L. I. (1996) · Infectious Disease Clinics of North America · doi:10.1016/s0891-5520(05)70332-9 · Cited by 14
Hepatitis A Virus
Robertson, B. H., & Bell, B. P. (2003) · Wiley eBooks · doi:10.1038/npg.els.0001026 · Cited by 14
Functional recombinant human anti-HBV antibody expressed in milk of transgenic mice
Zhang, R., Cui, D., Wang, H., Li, C., Yao, X., Zhao, Y., Liang, M., & Li, N. (2012) · Transgenic Research · doi:10.1007/s11248-012-9589-z · Cited by 13
“Besides, in different culture conditions, there are pitfalls in complicated purification steps as well as variable mAbs levels and posttranslational modifications (Castillo 1999; Farid 2007; Kozlowski and Swann 2006; Winokur and Stapleton 1992) .”
Background
Recommendations for Prevention of Hepatitis A Based on a Cost-Effectiveness Analysis
Tormans, G., Damme, P. V., & van Doorslaer, E. K. A. (1994) · Journal of Travel Medicine · doi:10.1111/j.1708-8305.1994.tb00579.x · Cited by 13
Hepatitis A Vaccines
Averhoff, F. M., Khudyakov, Y. E., & Nelson, N. P. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35761-6.00024-9 · Cited by 12
Recombinant Hepatitis A Virus Antigen: Improved Production and Utility in Diagnostic Immunoassays
LaBrecque, F. D., LaBrecque, D. R., Klinzman, D., Perlman, S. M., Cederna, J. B., Winokur, P. L., Han, J., & Stapleton, J. T. (1998) · Journal of Clinical Microbiology · doi:10.1128/jcm.36.7.2014-2018.1998 · Cited by 12
Effectiveness of immune globulins in preventing infectious hepatitis and hepatitis A: a systematic review
Bianco, E., MASI, S. D., Mele, A., & Jefferson, T. (2004) · Digestive and Liver Disease · doi:10.1016/j.dld.2004.07.014 · Cited by 12
“The protection conferred by IG seems to be short lived and requires early diagnosis and timely administration to contacts [5].”
Background
Virosomal Hepatitis A Vaccine (Strain RG-SB)
Lea, A. P., & Balfour, J. A. B. (1997) · BioDrugs · doi:10.2165/00063030-199707030-00006 · Cited by 12
Prevention and control of hepatitis A
(1994) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.1994.3229 · Cited by 12
An epidemiologic study on the seropositive rate of hepatitis A virus among a selected group of children and adults in Busan
Kwon, Y. O., Choi, I. J., Jung, J. W., & Park, J. H. (2007) · Korean Journal of Pediatrics · doi:10.3345/kjp.2007.50.3.262 · Cited by 11
Hepatitis vaccines
Karayiannis, P., Main, J., & Thomas, H. C. (2004) · British Medical Bulletin · doi:10.1093/bmb/ldh024 · Cited by 11
Hepatitis A vaccines
Murphy, T. V., Feinstone, S. M., & Bell, B. P. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-0090-5.00008-2 · Cited by 10
Inactivated Hepatitis A Vaccine (HM175 Strain)
Wagstaff, A. J., Plosker, G. L., & Balfour, J. A. B. (1996) · BioDrugs · doi:10.1007/bf03259353 · Cited by 10
Emerging Infections: Hepatitis A
Dentinger, C. (2009) · AJN American Journal of Nursing · doi:10.1097/01.naj.0000358491.84054.09 · Cited by 9
Considerations for the development of recommendations for the use of hepatitis A vaccine
Margolis, H. S., & Shapiro, C. N. (1993) · Journal of Hepatology · doi:10.1016/s0168-8278(05)80380-0 · Cited by 9
Hepatitis A Virus
Stapleton, J. T. (1999) · Humana Press eBooks · doi:10.1007/978-1-59259-702-4_2 · Cited by 8
Relative importance of the enterically transmitted human hepatitis viruses type A and E as a cause of foreign travel associated hepatitis
Langer, B., & Frösner, G. (1996) · Springer eBooks · doi:10.1007/978-3-7091-7482-1_14 · Cited by 8
Laboratory Testing for Viral Hepatitis
Harris, K. R., & Dighe, A. S. (2002) · Pathology Patterns Reviews · doi:10.1309/mauw-9059-dqa6-rmrj · Cited by 7
Amino acid interaction networks provide a new lens for therapeutic antibody discovery and anti-viral drug optimization
Viswanathan, K., Shriver, Z. H., & Babcock, G. J. (2015) · Current Opinion in Virology · doi:10.1016/j.coviro.2015.03.019 · Cited by 7
“exposure, and efficacy is even higher when administered early in the incubation period [7].”
Background
Hepatitis A, B, and C
Gilson, R. J. C., & Brook, M. G. (2006) · Sexually Transmitted Infections · doi:10.1136/sti.2006.023218 · Cited by 7
VÍRUS ENTÉRICOS NA LAGOA RODRIGO DE FREITAS
Vieira, C. B., Mendes, A. C. D. O., de Oliveira, J. M., Gaspar, A. M. C., Leite, J. P. G., & Miagostovich, M. P. (2012) · Oecologia Australis · doi:10.4257/oeco.2012.1603.13 · Cited by 7
PREPARING THE INTERNATIONAL TRAVELER
Nettleman, M. D. (1996) · Gastroenterology Clinics of North America · doi:10.1016/s0889-8553(05)70258-2 · Cited by 7
Dose range evaluation of a new inactivated hepatitis A vaccine administered as a single dose followed by a booster
Minutello, M., Zotti, C. M., Orecchia, S., Martino, E. D., Bastianoni, I., Ypma, E., Moiraghi, A. R., & Podda, A. (2000) · Vaccine · doi:10.1016/s0264-410x(00)00156-0 · Cited by 7
Hepatitis A Prophylaxis
Adler, R., & Shouval, D. (1996) · BioDrugs · doi:10.1007/bf03259088 · Cited by 7
Hepatitis A Virus
Feng, Z., & Lemon, S. M. (2014) · ASM Press eBooks · doi:10.1128/9781555816698.ch24 · Cited by 6
Mucosal Immunisation for Enteric Diseases
Sabbaj, S., Kiyono, H., & McGhee, J. R. (1997) · BioDrugs · doi:10.2165/00063030-199707020-00006 · Cited by 6
Viral Hepatitis
Neuhoff, B. K. (2025) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0000000000000938 · Cited by 6
Hepatitis A Cases Among Food Handlers: A Local Health Department Response—New York City, 2013
Ridpath, A., Reddy, V., Layton, M., Misener, M., Scaccia, A., Starr, D. T., Stavinsky, F., Varma, J. K., Waechter, H., Zucker, J. R., et al. (2017) · Journal of Public Health Management and Practice · doi:10.1097/phh.0000000000000526 · Cited by 5
Allogenic bone marrow transplantation with a donor presenting with an acute hepatitis A
Ghez, D., Nicand, É., Ferré, V., de Tailly, P. D., Coppo, P., Lenoir, B., Buisson, Y., Nedellec, G., & de Revel, T. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(00)00056-8 · Cited by 5
Foodborne Viral Hepatitis
Appleton, H., Banks, M., Dentinger, C., & Teo, C. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-501-5_7 · Cited by 5
Solvent/detergent treatment does not alter the tolerance or uptake of human normal immunoglobulin for intramuscular injection
Mould, G. P., Sutton, J. A., Matejtschuk, P., Gascoigne, E. W., & Dash, C. H. (2001) · Vox Sanguinis · doi:10.1046/j.1423-0410.2001.00026.x · Cited by 5
High immunogenicity and good tolerability of a new hepatitis A vaccine candidate
Langer, B. (1996) · Vaccine · doi:10.1016/0264-410x(96)00080-1 · Cited by 5
Hepatitis A: infection, detection, vaccination and immunity
van Hattum, J. (1999) · The Netherlands Journal of Medicine · doi:10.1016/s0300-2977(99)00073-x · Cited by 4
No evidence of transmission from an acute case of hepatitis A in a foodhandler: follow-up of almost 1,000 potentially exposed individuals, London, United Kingdom, April 2012
Hall, V. J., Abrahams, A., Turbitt, D., Cathcart, S., Maguire, H., & Balasegaram, S. (2014) · Eurosurveillance · doi:10.2807/1560-7917.es2014.19.30.20865 · Cited by 4
“Secondary cases can be averted by timely administration of post-exposure HAV vaccination, up to two weeks after exposure, and human normal immunoglobulin (HNIG) can be given to those most vulnerable to infection (those aged over 50 years or with comorbidities) up to 28 days post exposure [1,8-10].”
Background
Immunisation against hepatitis A — active or passive?
Iwarson, S. A. (1996) · Infection · doi:10.1007/bf01780641 · Cited by 4

Authors: Winokur, P. L., & Stapleton, J. T.
Affiliations: University of Iowa (US)
Corresponding author: Stapleton, J. T.
ORCID: Winokur, P. L.
Stapleton, J. T.
Venue: Clinical Infectious Diseases
Publisher: Oxford University Press (OUP)
Published: 1992-02-01
Volume: 14
Issue: 2
Pages: 580-586
ISSN: 1058-4838 (ISSN-L)
1537-6591
DOI: 10.1093/clinids/14.2.580
OpenAlex: W2017352315
Cited by: 136
References: 73
Citations by year: 2025: 1 · 2023: 1 · 2022: 2 · 2021: 3 · 2020: 2 · 2018: 1 · 2017: 4 · 2016: 2 · 2015: 2 · 2014: 3 · 2013: 2 · 2012: 3
FWCI: 5.47
Type: journal article
Language: en
Open access: closed
Locations: Clinical Infectious Diseases (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Hepatology › Hepatitis Viruses Studies and Epidemiology
Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
Health Sciences › Medicine › Infectious Diseases › Viral gastroenteritis research and epidemiology
Keywords: hepatitis A, immunoglobulin prophylaxis, hepatitis A virus, inactivated vaccine, live attenuated vaccine, vaccine immunogenicity, antibody response, post-exposure prophylaxis
MeSH terms: Hepatitis A, Humans, Immunization, Passive

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Immunoglobulin prophylaxis for hepatitis A.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks